Advertisement

Millennium: The Takeda Oncology Company, of Cambridge and Seattle Genetics Inc. of Bothell, Wash., said today that they have started a Phase 3 clinical trial to evaluate Adcetris, a drug candidate they are jointly developing for patients with CD30-expressing relapsed cutaneous T-cell lymphoma. Cutaneous T-cell lymphoma is a group of non-Hodgkin lymphomas that are cancers of the T lymphocytes (a type of white blood cell) mainly affecting the skin but that can also involve the blood, lymph nodes and/or internal organs in patients with advanced disease.

SOURCE

Advertisement
Advertisement